The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis PatientsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared gut microbiome composition between 31 healthy controls and 46 patients with active pulmonary tuberculosis. The goal was to characterize gut microbiota changes linked to Mycobacterium tuberculosis infection through the gut-lung axis.
How was it studied?
The team used shotgun metagenomic sequencing of stool samples from both groups. They assessed species diversity, metabolic pathway abundance, and built a classification model from selected bacterial species abundances.
What did they find?
TB patients had markedly lower gut species number and microbial diversity than healthy controls. Short-chain fatty acid producing bacteria and their associated metabolic pathways were strikingly decreased in TB patients. A three-species model using Haemophilus parainfluenzae, Roseburia inulinivorans, and Roseburia hominis abundance discriminated healthy from diseased states. Bacteroides vulgatus SNP patterns also distinguished the two groups.
Why it matters
These gut microbiota signatures could inform new non-invasive diagnostic approaches for pulmonary tuberculosis. The findings also point to SCFA-producing bacteria as a potential target for future TB treatment strategies.